Press Releases

Date	Title
June 15, 2021	Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical
June 10, 2021	Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors
May 6, 2021	Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results
May 6, 2021	Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)
May 6, 2021	Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer
April 29, 2021	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
March 15, 2021	Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess
March 1, 2021	Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer
February 23, 2021	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results
February 8, 2021	Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update